INDIVIDUAL ARTICLE: Real-World Cases of Clascoterone Topical Treatment for Acne and Related Disorders
Acne vulgaris affects approximately 80% of young adults and adolescents in the world. Acne presents as comedones, pustules, papules, and nodules on the face, chest, shoulders, or back. It can lead to a significant decrease in quality of life with a high risk of associated depression and anxiety. Hyperstimulation of sebaceous glands by androgens play a pivotal role in acne pathogenesis. Clascoterone 1% cream is a first-in-class topical androgen receptor inhibitor approved for treatment of acne in patients 12 years and older. In the following real-world cases, expert dermatologists demonstrate use of clascoterone cream as monotherapy or in combination with other agents to treat acne in a variety of patients. Experts found that twice-daily use led to best overall results with patients. Real-world cases serve as invaluable guides for patients and dermatologists to help form personalized, targeted acne regimens. J Drugs Dermatol. 2025;24:1(Suppl 2):s3-10.
Authors
- Anneke Andriessen (ORCID: https://orcid.org/0000-0001-5930-4162)
- Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
- Monica Li
- Elena Netchiporouk (ORCID: https://orcid.org/0000-0002-6692-7787)
- Andrei I. Metelitsa (ORCID: https://orcid.org/0000-0001-5482-680X)
- Sonya Abdulla
- Sam Hanna
- Fatemeh Jafarian (ORCID: https://orcid.org/0000-0002-9267-3557)
- Jennifer Lipson (ORCID: https://orcid.org/0000-0001-8601-2480)
- Christopher D. Sibley
- Jerry Tan
- Jaggi Rao MSc
- Barbara Miedrzybrodzski
Publication Details
- Journal
- Journal of Drugs in Dermatology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.36849/jdd.73361
- Citations
- 3
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 1.60